Overview

This trial is active, not recruiting.

Condition hepatitis c, chronic
Treatment vgx-6150
Phase phase 1
Sponsor GeneOne Life Science, Inc.
Collaborator Inovio Pharmaceuticals
Start date January 2014
End date July 2015
Trial size 18 participants
Trial identifier NCT02027116, VGX-6150-01

Summary

To evaluate the safety, tolerability and immunogenicity of VGX-6150 as second-line therapy in chronic hepatitis C patients

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Subjects will receive a 3 dose series of VGX-6150 containing 1mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
vgx-6150
Plasmid DNA delivered via IM injection with electroporation
(Experimental)
Subjects will receive a 3 dose series of VGX-6150 containing 3mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
vgx-6150
Plasmid DNA delivered via IM injection with electroporation
(Experimental)
Subjects will receive a 3 dose series of VGX-6150 containing 6mg DNA/dose administered via IM injection + electroporation at Day 0, Week 4, Week 8, Week 12
vgx-6150
Plasmid DNA delivered via IM injection with electroporation

Primary Outcomes

Measure
Safety and Tolerability
time frame: Screening ~ week 36

Secondary Outcomes

Measure
Immunogenicity and virologic response
time frame: Screening ~ Week 36

Eligibility Criteria

Male or female participants from 19 years up to 65 years old.

Inclusion Criteria: - Subjects who want to participate in this trial should meet all of the following criteria. 1. Male or females aged 19 to 65 years 2. Chronic hepatitis C patients infected with HCV genotype 1a or 1b 3. Patients who failed* SOC therapy with PEG-IFN and ribavirin or triple therapy with SOC and DAA agents *Treatment failure is defined by any of the following; A. Partial response (PR) Serum HCV RNA level declined by at least 2 log10 but still detected at treatment week 24 B. Non-response (NR) Serum HCV RNA level not declined by at least 2 log10 at treatment week 12 C. Relapse Serum HCV RNA undetected during treatment but detectable after end of treatment D. Treatment discontinuation due to ADR or other reason 4. Patients whose deltoid muscles (left or right) are accessible by 12 to 19 mm cannula/ electrode for intramuscular (IM) injection and electroporation (EP) 5. Patients who can comply with planned schedule of this protocol 6. Patients who give written informed consent voluntarily Exclusion Criteria: - Subjects who meet any of the followings cannot participate in this study. 1. Liver transplant recipients 2. Patients having decompensated liver cirrhosis with any history or evidence of ascites, esophageal variceal hemorrhage and/or hepatic encephalopathy 3. Malignant tumor patients who received radiotherapy or chemotherapy before study participation 4. Current active infection except hepatitis C that requires medical treatment 5. Autoimmune disease patients or immunodeficient (immuno-compromised) patients 6. Patients who received immunomodulators, cytotoxic agents or systemic corticosteroids for chronic disease other than hepatitis C within 2 months before study participation 7. Patients who received non-steroidal anti-inflammatory drugs (NSAIDs) within 10 days before IP administration 8. Concomitant diseases which is judged to be unacceptable for study participation by investigator (e.g., severe cardiovascular, renal , or psychiatric disease) 9. Clinically significant abnormal findings in physical examination,laboratory tests, vital signs or ECG at investigator's discretion 10. Patients with implantable pacemaker 11. Patients with metal implant in IP administration area or nearby 12. Positive for HBsAg, or HIV Ab 13. Previous history of gene therapy 14. History of allergy or anaphylaxis to any component of IP or other vaccine 15. Patients who received major surgery within 4 weeks before IP administration 16. Blood transfusion within 4 weeks before IP administration 17. Current alcohol or drug abuse 18. Patients who received other vaccine within 30 days before IP administration 19. Pregnancy or breast-feeding woman 20. Women of childbearing potential (WOCBP) or men with partner of WOCBP who are unwilling to use adequate contraception or be abstinent during the trial 21. Patients who received other investigational products within 30 days before study participation 22. Patients incapable of participating in this trial by investigator's judgment

Additional Information

Official title Multi-center, Open-label, Dose Escalation, Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection
Principal investigator Sang Hoon Ahn, M.D, Ph.D.
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by GeneOne Life Science, Inc..